Inhibrx Stock Performance

INBX -  USA Stock  

USD 38.46  1.45  3.63%

On a scale of 0 to 100, Inhibrx holds a performance score of 8. The company retains a Market Volatility (i.e., Beta) of 0.4753, which attests to possible diversification benefits within a given portfolio. Let's try to break down what Inhibrx's beta means in this case. As returns on the market increase, Inhibrx returns are expected to increase less than the market. However, during the bear market, the loss on holding Inhibrx will be expected to be smaller as well. Although it is vital to follow Inhibrx current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The philosophy towards determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-eight technical indicators for Inhibrx, which you can use to evaluate the performance of the firm. Please utilizes Inhibrx potential upside, and the relationship between the total risk alpha and kurtosis to make a quick decision on whether Inhibrx current trending patterns will revert.

Inhibrx Stock Performance 

 Inhibrx Performance
8 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Inhibrx are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile fundamental drivers, Inhibrx showed solid returns over the last few months and may actually be approaching a breakup point. ...more

Inhibrx Price Channel

Quick Ratio3.89
Fifty Two Week Low14.27
Target High Price45.00
Fifty Two Week High50.97
Target Low Price35.00

Inhibrx Relative Risk vs. Return Landscape

If you would invest  2,877  in Inhibrx on July 22, 2021 and sell it today you would earn a total of  969.00  from holding Inhibrx or generate 33.68% return on investment over 90 days. Inhibrx is currently generating 0.5526% in daily expected returns and assumes 4.5774% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Inhibrx, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Inhibrx is expected to generate 6.38 times more return on investment than the market. However, the company is 6.38 times more volatile than its market benchmark. It trades about 0.12 of its potential returns per unit of risk. The DOW is currently generating roughly 0.05 per unit of risk.

Inhibrx Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibrx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inhibrx, and traders can use it to determine the average amount a Inhibrx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1207

Good Returns
Average Returns
Small ReturnsINBX
Negative Returns
Estimated Market Risk
  actual daily
 39 %
of total potential
Expected Return
  actual daily
 10 %
of total potential
Risk-Adjusted Return
  actual daily
 8 %
of total potential
Based on monthly moving average Inhibrx is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inhibrx by adding it to a well-diversified portfolio.

About Inhibrx Performance

To evaluate Inhibrx Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Inhibrx generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Inhibrx Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Inhibrx stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Inhibrx's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Return on Average Assets(0.89) (0.97) 
Return on Average Equity 8.41  7.06 
Return on Invested Capital(2.28) (2.46) 
Return on Sales(5.07) (5.47) 
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.

Things to note about Inhibrx

Checking the ongoing alerts about Inhibrx for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Inhibrx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Inhibrx Alerts

Equity Alerts and Improvement Suggestions

Inhibrx appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 12.9 M. Net Loss for the year was (75.32 M) with loss before overhead, payroll, taxes, and interest of (60.61 M).
Inhibrx currently holds about 107.99 M in cash with (62.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.86.
Inhibrx has a poor financial position based on the latest SEC disclosures
Roughly 40.0% of the company shares are held by company insiders
Latest headline from Inhibrx falls 0.73 percent on Moderate Volume October 15 -
Please see Risk vs Return Analysis. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Correlations
Find global opportunities by holding instruments from different markets
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.